الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Fluconazole (FLZ) is a synthetic triazole antifungal drug for the treatment of superficial and systemic fungal infection with possible drawback of itching in topical therapy.
FLZ has shown activity against yeasts, yeast-like dimorphic fungi, Candida spp., Blastomyces dermatitidis, Cryptococcus neoformans, Epidermophytom spp., Histoplasma, Microsporum spp., and Trichophyton spp.
Oral administration of high dose of FLZ often produces gastric irritation, heartburn, vomiting and sometimes patient can develop ulceration and there is less patient compliance with long term therapy. Furthermore, oral FLZ is reported to interact with a number of medications, including oral hypoglycemics, coumarin-type anticoagulants, cyclosporins, terfenadin, theophylline, phenytoin, rifampin and astemizole .
The FLZ semisolid dosage form applied three times daily has demonstrable activity against fungal infection but conventional topical gel preparations are less acceptable to patients due to their high viscosity, leading to inappropriate application to skin lesions. In addition, the systemically absorbed fraction of the dose is excreted in the urine.
Thus, for effective and controlled release topical antifungal therapy with enhanced drug deposition into the skin, the cutaneous availability of FLZ needs to be modulated; a need that can be met by a suitable drug delivery system with advantage of reducing frequent dosing hence, less side effect and more patient comfort.